Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$51.80

1.24 (2.45%)

09:22
11/21/16
11/21
09:22
11/21/16
09:22

Kite to present interim results from ZUMA-1 pivotal trial at ASH meeting

Kite Pharma announced that data from the interim analysis of the pivotal ZUMA-1 trial of KTE-C19 in patients with chemorefractory aggressive non-Hodgkin lymphoma have been accepted as an oral late-breaking presentation at the American Society of Hematology, or ASH, 58th Annual Meeting in San Diego, CA, on December 6, 2016. The abstract was one of only six accepted in this category and will be included in the December 1 online issue of Blood. Kite reports that KTE-C19 significantly improved Objective Response Rate in patients with Chemorefractory DLBCL at pre-defined interim analysis. "Outcomes for patients with aggressive NHL depend on whether their disease is sensitive to chemotherapy. The ZUMA-1 study was designed to support registration of KTE-C19 by enrolling a well-defined chemorefractory patient population. We are pleased with the outcome of the study to date and thank the patients and investigators for their participation in the first positive pivotal study in CAR-T therapy," said Jeff Wiezorek, M.D., Senior VP of Clinical Development of Kite.

  • 03

    Dec

  • 03

    Dec

KITE Kite Pharma
$51.80

1.24 (2.45%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.

TODAY'S FREE FLY STORIES

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

, NVS

Novartis

$74.36

0.955 (1.30%)

12:57
04/24/17
04/24
12:57
04/24/17
12:57
Periodicals
J&J, Novartis, Takeda in talks over Hypermarcas takeover, Reuters says »

Johnson & Johnson…

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

NVS

Novartis

$74.36

0.955 (1.30%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

HYPMY

Hypermarcas

$9.66

0.44 (4.77%)

BBD

Banco Bradesco

$10.17

0.33 (3.35%)

CS

Credit Suisse

$15.16

0.705 (4.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

  • 26

    Jun

REED

Reed's

12:56
04/24/17
04/24
12:56
04/24/17
12:56
Hot Stocks
Breaking Hot Stocks news story on Reed's »

Reed's trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

, W

Wayfair

$46.66

0.7 (1.52%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Periodicals
Amazon hopes to launch furniture seller program, Furniture Today reports »

In a report highlighted…

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

W

Wayfair

$46.66

0.7 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 09

    May

  • 16

    May

  • 17

    May

  • 23

    May

MMM

3M

$193.60

2.1 (1.10%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Technical Analysis
3M technical notes before earnings news »

The stock has recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

CAT

Caterpillar

$96.85

2.53 (2.68%)

12:52
04/24/17
04/24
12:52
04/24/17
12:52
Earnings
On The Fly: What to watch in Caterpillar earnings report »

Caterpillar (CAT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 14

    Jun

MU

Micron

$27.32

-0.64 (-2.29%)

12:51
04/24/17
04/24
12:51
04/24/17
12:51
Options
Bullish sentiment in Micron May 5th options ahead of a company event »

Bullish sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 07

    Jun

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:50
04/24/17
04/24
12:50
04/24/17
12:50
Periodicals
Akorn close to buyout deal at $33-$35/share, Reuters reports »

Akorn (AKRX) is near a…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$89.22

1.23 (1.40%)

12:49
04/24/17
04/24
12:49
04/24/17
12:49
Hot Stocks
Fitch: Mexican regulation could pressure Kansas City Southern »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:47
04/24/17
04/24
12:47
04/24/17
12:47
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Sources: Fresenius could…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:44
04/24/17
04/24
12:44
04/24/17
12:44
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Fresenius nears deal to…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$70.71

2 (2.91%)

12:41
04/24/17
04/24
12:41
04/24/17
12:41
Options
Notable call write in Comerica as shares rally »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CRHM

CRH Medical

$5.75

-1.6 (-21.77%)

12:40
04/24/17
04/24
12:40
04/24/17
12:40
Recommendations
CRH Medical analyst commentary  »

Cantor discusses recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Google adds TV to 'DoubleClick' ad buying platform »

Google announced in its…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

ORAN

Orange SA

$15.98

0.935 (6.22%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Orange partners with Facebook to launch startup accelerator »

Orange is working with…

ORAN

Orange SA

$15.98

0.935 (6.22%)

FB

Facebook

$143.68

-0.12 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

BIIB

Biogen

$272.94

0.48 (0.18%)

12:32
04/24/17
04/24
12:32
04/24/17
12:32
Technical Analysis
Biogen technical remarks ahead of earnings news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 31

    May

XOP

SPDR Oil Exploration and Production Fund

$35.41

0.3 (0.85%)

12:31
04/24/17
04/24
12:31
04/24/17
12:31
Options
Defensive option play in SPDR Oil Exploration and Production ETF »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$116.82

-1.9 (-1.60%)

12:26
04/24/17
04/24
12:26
04/24/17
12:26
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 23

    Oct

MCK

McKesson

$136.22

0.3 (0.22%)

, TSRO

Tesaro

$136.01

-3 (-2.16%)

12:26
04/24/17
04/24
12:26
04/24/17
12:26
Hot Stocks
Biologics Inc says selected as specialty pharmacy provider for Tesaro's Zejula »

Biologics Inc, a McKesson…

MCK

McKesson

$136.22

0.3 (0.22%)

TSRO

Tesaro

$136.01

-3 (-2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 30

    Jun

AGN

Allergan

$238.06

1.71 (0.72%)

, BIIB

Biogen

$272.94

0.48 (0.18%)

12:25
04/24/17
04/24
12:25
04/24/17
12:25
Conference/Events
Piper Jaffray biopharma analysts hold an analyst/industry conference call »

Biopharmaceuticals…

AGN

Allergan

$238.06

1.71 (0.72%)

BIIB

Biogen

$272.94

0.48 (0.18%)

CARA

Cara Therapeutics

$16.53

-0.56 (-3.28%)

COLL

Collegium Pharmaceutical

$10.24

0.19 (1.89%)

EGLT

Egalet

$4.24

0.02 (0.47%)

ENDP

Endo

$10.29

-0.19 (-1.81%)

NKTR

Nektar

$18.37

-0.76 (-3.97%)

PFE

Pfizer

$33.82

0.18 (0.54%)

TEVA

Teva

$31.81

0.68 (2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 07

    May

  • 09

    May

  • 11

    May

  • 31

    May

  • 06

    Jun

  • 08

    Jun

  • 27

    Aug

  • 30

    Aug

SNAP

Snap

$21.19

0.26 (1.24%)

, YHOO

Yahoo

$47.52

-0.15 (-0.31%)

12:17
04/24/17
04/24
12:17
04/24/17
12:17
Hot Stocks
Yahoo discloses stake in Snap »

In the "Schedule of…

SNAP

Snap

$21.19

0.26 (1.24%)

YHOO

Yahoo

$47.52

-0.15 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

$NSD

NASDAQ Market Internals

12:17
04/24/17
04/24
12:17
04/24/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
04/24/17
04/24
12:16
04/24/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCR

C.R. Bard

$304.26

51.19 (20.23%)

, BDX

Becton Dickinson

$179.40

-5.89 (-3.18%)

12:14
04/24/17
04/24
12:14
04/24/17
12:14
General news
On The Fly: Top stock stories at midday »

Stocks opened with huge…

BCR

C.R. Bard

$304.26

51.19 (20.23%)

BDX

Becton Dickinson

$179.40

-5.89 (-3.18%)

PPG

PPG

$107.45

1.51 (1.43%)

AKZOY

AkzoNobel

$27.96

-0.11 (-0.39%)

HAS

Hasbro

$96.03

0.02 (0.02%)

SRPT

Sarepta

$32.61

0.07 (0.22%)

SBH

Sally Beauty

$19.20

-0.49 (-2.49%)

HLX

Helix Energy

$6.41

-0.68 (-9.59%)

HAL

Halliburton

$47.15

0.09 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 26

    Apr

  • 01

    May

  • 01

    May

  • 03

    May

  • 04

    May

  • 17

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

CAT

Caterpillar

$96.65

2.33 (2.47%)

12:13
04/24/17
04/24
12:13
04/24/17
12:13
Technical Analysis
Caterpillar technical comments ahead of earnings »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 14

    Jun

WFT

Weatherford

$5.43

-0.04 (-0.73%)

12:11
04/24/17
04/24
12:11
04/24/17
12:11
Options
Weatherford calls active ahead of earnings »

Weatherford calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 15

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.